Primecap Management Co/Ca/ built an about 14.36% stake in OncoMed Pharmaceuticals, Inc. (OMED)

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) is now up 29.5% compared to a 12-month low of $0.55. We have seen the price to move -2.67% lower and get settled at $0.71 on 01/11/2019. At recent session, it appeared stuck in a range of $0.6916 to $0.7414. This company shares are 111.27% off its target price of $1.5 and the current market capitalization stands at $28.1M. The recent change has given its price a -37.85% deficit over SMA 50 and -80.44% deficit over its 52-week high. The stock witnessed -25.47% declines, -65.29% declines and -70.86% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found OMED’s volatility during a week at 8.64% and during a month it has been found around 14.07%.

OncoMed Pharmaceuticals, Inc. (OMED) Top Holders

Institutional investors currently hold around $13 million or 69.9% in OMED stock. Look at its top three institutional owners. Primecap Management Co/Ca/ owns $4.04 million in OncoMed Pharmaceuticals, Inc., which represents roughly 14.36% of the company’s market cap and approximately 31.04% of the institutional ownership. Similar statistics are true for the second largest owner, Bvf Inc/Il, which owns 4,042,989 shares of the stock are valued at $2.86 million. The third largest holder is Perceptive Advisors Llc, which currently holds $1.86 million worth of this stock and that ownership represents nearly 6.6% of its market capitalization.

OncoMed Pharmaceuticals, Inc. 13F Filings

At the end of September reporting period, 25 institutional holders increased their position in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) by some 1,689,634 shares, 32 decreased positions by 1,918,191 and 14 held positions by 15,332,655. That puts total institutional holdings at 18,940,480 shares, according to SEC filings. The stock grabbed 8 new institutional investments totaling 1,349,061 shares while 17 institutional investors sold out their entire positions totaling 1,705,531 shares.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Insider Trades

Multiple company employees have indulged in significant insider trading. OncoMed Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Gurney Austin has sold 11,117 shares of OncoMed Pharmaceuticals, Inc. (OMED) in trading session dated Dec. 24, 2018. These shares are worth $6,670 and were traded at $0.6 each. The SEC filing shows that Lewicki John A. performed a sale of 1,156 shares. The President & CEO disposed these shares by way of transaction on Oct. 10, 2018. The company’s shares were given away at $2.01 per share worth to an income of some $2,324 on account of Lewicki John A..

SVP & General Counsel, Hager Alicia J., sold 1,156 common shares of OncoMed Pharmaceuticals, Inc. (OMED) in the open market. In a transaction dated Oct. 10, 2018, the shares were put up for sale at an average price of $2.02, raking in a sum of $2,335. After this sale, 51,754 common shares of OMED are directly owned by the insider, with total stake valued at $36,745.

In the transaction dated Oct. 10, 2018, the great number of shares disposed came courtesy the; Gurney Austin disposed a total of 1,156 shares at an average price of $2.01, amounting to approximately $2,324. The insider now directly owns 77,924 shares worth $55,326.

OncoMed Pharmaceuticals, Inc. (OMED) Analyst Guide

Several analysts have released their opinion on OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), with 2 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.67 average brokerage recommendation.